Objective: The purpose of this study was to evaluate whether maximal aortic diameter affects outcome after endovascular aneurysm repair (EVAR) of abdominal aortic aneurysm (AAA).
Abdominal aortic aneurysm (AAA) is the most common aneurysm, and rupture continues to be the most frequent and lethal complication. To prevent AAA rupture, open repair (OR) used to be the "gold standard"; however, with the advent of endovascular aneurysm repair (EVAR) 1 and development of endovascular technology, the use of EVAR in the United States has increased from 5.2% in 2000 to 74% in 2010. 2 At our institution, the proportion of EVAR for asymptomatic AAA has been >70%. 3 In a recent publication on outcome of EVAR patients, we observed that clinical presentation predicted early mortality and complications and advanced age predicted all-cause mortality. 4 When we compared outcome after EVAR vs OR using propensity score modeling, maximal aortic diameter increase per 1 cm was a risk factor predicting late all-cause mortality. 3 The current size threshold to recommend OR for asymptomatic AAAs in men has been established at 5.5 cm. [5] [6] [7] [8] [9] On the basis of two randomized controlled trials and evidence from single-institutional data, 10 this size has also been accepted as a threshold for EVAR. A report from the European Collaborators on Stent/graft Techniques for aortic Aneurysm Repair (EUROSTAR) registry, published in 2004, first called attention to the size of AAA as a factor predicting late outcome after EVAR. In this international registry of 4392 patients, the patients with large AAAs ($6.5 cm) after EVAR had the highest rate of all-cause and aneurysm-related death and late aneurysm rupture. 11 Outcome of patients with small (<5.5 cm) AAAs was excellent, similar to data reported by us 10 and others. 12 , 13 A review of long-term results of a prospective multicenter investigational device exemption clinical trial of EVAR found that patients with large AAAs ($6.0 cm) had a shorter life expectancy and a higher risk of rupture, surgical conversion, and aneurysm-related death compared with patients with smaller AAAs (<5.0 cm). 14 Others found that size of the aneurysm (#5.4 cm vs $5.5 cm) had no association with outcome after EVAR. 15 The association of AAA size and outcome after EVAR in early through recent experience has not been well established. The purpose of this study was to evaluate whether maximal aortic diameter is associated with outcome after EVAR performed for asymptomatic nonruptured AAA at a tertiary medical center.
METHODS
Study population. Clinical data of consecutive patients who underwent EVAR for nonruptured asymptomatic infrarenal AAA between January 1, 1997, and December 31, 2011, at Mayo Clinic, Rochester, Minnesota, were retrospectively reviewed. Patients with maximum external diameter of AAA measured by computed tomography (CT) or CT angiography (CTA), according to reporting standards for EVAR, 16 were included. Patients who received physician-modified, research trial, or branched or fenestrated endografts during the study period were excluded. Demographic data, comorbidities, diagnostic and laboratory results, interventional records, mortalities, complications, reinterventions, and ruptures were abstracted from the Mayo Clinic Aortic Registry. The primary end point was all-cause mortality; secondary end points were complications, reinterventions, and ruptures. Adverse events that occurred within 30 days after the index procedure were defined as early or 30-day results; those that occurred after 30 days were defined as late results. Informed consent of the patients was obtained for the study; this study was approved by the Mayo Foundation Institutional Review Board. Indications for EVAR included asymptomatic, nonruptured infrarenal AAA patients with a maximal aortic diameter $5.5 cm in diameter in men and $5.0 cm in women as recommended by the Society for Vascular Surgery (SVS) guidelines. 17 Those with smaller aneurysms included rapid growth (>0.5 cm/y); overly anxious patients, especially those with a family history of AAA; and smaller AAAs with large (>3.5 cm) or rapidly growing associated iliac artery aneurysm. EVAR was performed on patients with eligible aortoiliac artery anatomy confirmed by preoperative CTA. 3, 4 Patients were classified into four groups based on the diameter of AAA: group 1, diameter < 5.0 cm; group 2, 5.0 cm # diameter < 5.5 cm; group 3, 5.5 cm # diameter < 6.0 cm; group 4, diameter $ 6.0 cm. SVS comorbidity scores were used to stratify patients into low/normal-risk (score # 10) or high-risk category (score > 10).
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Procedure. The procedure of EVAR was described previously. 3, 4 Briefly, EVAR was performed using aortobi-iliac endografts. Aortouni-iliac endograft was used in patients with contralateral iliac artery occlusive disease followed by femoral-femoral bypass grafting. Straight endograft placement was performed on selected patients with AAA confined to abdominal aorta with sufficient landing zone to the bifurcation, usually early in the experience. Staged or simultaneous embolization of the internal iliac artery was performed on patients with iliac artery aneurysms or when stent graft extension beyond the iliac bifurcation was required.
Follow-up. Patients were asked to return at 1 to 3 months after EVAR for physical examination and imaging studies including CT scanning and duplex ultrasound and every 6 months afterward. Follow-up information including reinterventions was obtained from the medical records and mailing questionnaires. The patient's vital status was established from charts, mailing questionnaire, death certificate, or autopsy report.
Definitions. Technical success was defined as successful deployment of the device without complication or conversion surgery. Complications were identified using the criteria of the SVS Vascular Quality Initiative. 19 Procedure-related and device-related complications were defined according to SVS reporting standards. 20 Types of endoleak were defined as described in SVS practice guidelines. 17 Statistical analyses. Descriptive statistics, including means, medians, standard deviations, ranges, and proportions, were reported as appropriate. Analysis of variance test and Kruskal-Wallis test were performed for means and medians, respectively, among groups. The association of a patient or surgical variable with the odds of 30-day outcome was assessed using logistic regression. Results were reported as odds ratio and 95% confidence interval (CI). Rates of survival, freedom from complication, reintervention, and rupture were estimated using the Kaplan-Meier method. Univariate and multiple variable models assessing the association of gender, age, maximal aortic diameter of AAA category, surgical risk, cancer history, and types of endografts with these outcomes were assessed using Cox proportional hazards regression. Results of these models were reported as hazard ratio (HR) and 95% CI. P values < .05 were considered statistically significant in all analyses. Analyses were performed using SAS 9.2 software (SAS Institute, Cary, NC).
RESULTS
Demographic data. During the study period, 874 consecutive patients undergoing EVAR for nonruptured asymptomatic infrarenal AAA were included, after exclusion of eight patients with maximal aortic diameter measured by magnetic resonance angiography (Supplementary Table I Table I . The distribution of patients in terms of gender, age, and surgical risk significantly differed among the four groups (P < .05).
Intraoperative data. Intraoperative data are shown in Supplementary Table II (online only) . A straight aortic stent graft was placed in 11 patients (1.3%); an aortouni-iliac graft was used in 14 (1.6%). All patients received femorofemoral bypasses except two patients whose contralateral common and external iliac arteries were occluded; bifurcated aortobi-iliac stent graft was inserted in 849 (97%). The types of devices used included AneuRx, Excluder, Zenith, and other devices; 849 (97%) were aortobi-iliac, 14 (1.6%) were aortouni-iliac, and 11 (1.3%) were aortoaortic endografts. Of 874 patients, coil embolization or placement of an endovascular plug into one (n ¼ 88) or both internal iliac arteries (n ¼ 1) was done in 89 patients (10%), in 39 (44%) during a separate procedure before EVAR and in 51 (57%) together with EVAR; one patient had both preoperative and intraoperative embolization.
Technical success was 99.5%. Four patients (0.5%) had primary conversion surgery (group 1, 0; group 2, 1; group 3, 1; group 4, 2) because of unintentional coverage of the renal arteries (n ¼ 2), inability to advance the endograft beyond the external iliac artery (n ¼ 1), and AAA rupture (n ¼ 1). Intraoperatively, two patients (0.2%) died, one of AAA rupture from group 3, another of iliac artery rupture from group 4. Both deaths occurred during endograft deployment in patients treated before 2006.
Thirty-day results. Overall in-hospital and 30-day mortality rates were 0.7% (6/874) and 1.0% (9/874), respectively. Eight of the nine deaths occurred in high-risk patients (2.4% vs 0.2%; P ¼ .02). Except for two intraoperative deaths, causes of the remaining four inhospital deaths were paraplegia (n ¼ 1) from group 1 and cardiac complication (n ¼ 1), multiorgan failure (n ¼ 1), and ischemic colitis (n ¼ 1) from group 4. Three early deaths occurred after discharge, one due to cardiac complications and two due to pulmonary complications from groups 1, 2, and 4 in each. Patients in group 4 had prolonged hospital stay (P < .05).
Univariate analysis revealed that both a 10-year increase in age and high risk were significant predictors for early mortality, whereas there was no significant association for age older than 80 years, maximal aortic diameter, or procedure period (Supplementary Table III , online only).
Overall 30-day complication rate was 13% (110/874); reintervention rate was 4.1% (36/874). There were no significant differences among the four groups (P > .05; Table II (Fig 2, A) . Patient group status was significantly associated with survival (P < .001). Compared with group 1, a patient in group 3 had 1.47-fold higher risk (95% CI, 1.01-2.14; P ¼ .04) and a patient in group 4 had 2.33-fold higher risk (95% CI, 1.64-3.32; P < .001) of having all-cause mortality (Table III) .
Both univariate and multivariable analyses revealed that a 10-year increase in age and age >80 years were associated with all-cause mortality. In addition, female gender, maximal aortic diameter $6.0 cm, cancer (13) 34 (14) 21 (9) a 46 (17) .04
Cancer history 211 (24) 24 (20) 58 (24) 64 (26) 65 (24) .63
Current smoker 152 (17) 23 (19) 43 (17) 36 (15) 50 (19 history, and type of endograft were also significant predictors for late all-cause mortality in univariate analysis (P < .05; Tables III and IV) . Univariate analysis did not reveal a significant association between all-cause mortality and the time period when the procedure was performed (HR, 0.80; P ¼ .07; (Table IV) . The overall 5-year freedom from complication rate was 65% (Fig 2, B Freedom from reintervention rate at 5 years was 74% (group 1, 80%; group 2, 72%; group 3, 76%; group 4, 71%). Group status was not significantly associated with risk of a reintervention (P ¼ .11). However, compared with group 1, group 2 had 1.67-fold increased risk (95% CI, 1.02-2.76; P ¼ .04) and group 4 had 1.87-fold increased risk (95% CI, 1.13-3.09; P ¼ .01) of having a reintervention.
Similar to complications, when we analyzed the different types of reinterventions (procedure, device, and endoleak related), we found no statistically significant difference among the four groups (P > .05), although there was an indication for group 4 relative to group 1 (HR, 2.0; 95% CI, 1.1-3.6; P ¼ .02). There were no significant differences in terms of procedure-, device-, and endoleakrelated reinterventions between patients undergoing procedures from 1997 to 2005 and patients undergoing procedures from 2006 to 2011 (P > .05).
Conversion rate to OR at 5 years was 2.4% (group 1, 0%; group 2, 1.7%; group 3, 3.0%; group 4, 3.8%). The risk of conversion was not significantly associated with group status (P ¼ .69).
Eight late ruptures (group 2, two; group 3, three; group 4, three) occurred at a mean of 5.1 years (range, 5.2 months-8.5 years) after EVAR; four patients had conversion to OR, two had endovascular repairs. Two high-risk patients elected for comfort care; one died at 1 month, the other at 8 months after rupture. Freedom from rupture rate at 5 years was 99% (group 1, 100%; group 2, 100%; group 3, 99%; group 4, 99%; P ¼ .36).
In the multiple variable models, maximal aortic diameter $6.0 cm (relative to <5.0 cm) was associated with increased risk of complications (P ¼ .009; Table V) and reinterventions (P ¼ .01; Supplementary Table IV, online only).
DISCUSSION
Size of the aneurysm is one of the strongest predictors of aneurysm rupture. [21] [22] [23] [24] Current guidelines of the SVS recommend elective repair of aneurysms when they reach 5.5 cm in men. 17 The UK Small Aneurysm Trial (SAT) 5 Endografting for Small Aneurysm Repair (CEASAR) trials, treating AAAs 4.0 to 5.0 cm and 4.1 to 5.4 cm, respectively. 13 For these reasons, small (<5.4 cm) AAAs are in general observed with annual ultrasound surveillance, unless they become symptomatic or grow exceedingly fast (>1 cm/y) or if the patients are overly anxious, especially those with a family history of ruptured aneurysm. Within the UK SAT and ADAM studies, women had a threefold to fourfold higher risk of rupture than men 6, 25, 26 ; thus, the SVS guidelines recommend a threshold for repair of AAA in women of 5.0 cm in diameter. 17, 27 Several studies found that patients with small AAAs have better early and late outcome after EVAR than patients with large aneurysms. 11, 16, 28 In addition, increasing AAA size has been shown to negatively affect the anatomic eligibility for EVAR, 29, 30 and patients with larger aneurysms are usually older, have more comorbidities, and are at higher surgical risk; all these factors would explain the increased mortality and morbidity of the patients. Most recently, Schermerhorn et al 31 reported on 39,966
propensity score-matched pairs of patients undergoing either OR or EVAR; using the Medicare database, perioperative mortality was 1.6% after EVAR, and it increased with age. Through 8 years of follow-up, rates of survival, aneurysm-related reintervention, and aneurysm rupture were 55%, 19%, and 5.4%, respectively, after EVAR. However, the maximal aortic diameter was not studied in this study. Our study, performed at a tertiary care institution on 874 consecutive patients, therefore focused on maximal aortic diameter as a predicting factor of early and late mortality and complications following elective repair of AAAs using EVAR. Size threshold did not change much in the past 10 years at our institution (Supplementary  Table I , online only). This study again confirmed that elective EVAR for asymptomatic nonruptured aneurysms can be performed with excellent results, with a 30-day overall mortality rate of 1.0% that increased to 2.4% in high-risk patients but was as low as 0.2% in low-to average-risk patients. These results are similar to those we reported earlier 3, 4 or those published of the National Inpatient Sample database 2 or reported by others. 11, 28, [32] [33] [34] The low overall early mortality was likely the reason we did not find differences in our subgroups. Factors associated with early mortality in our study included only advanced age and high surgical risk, similar to factors observed in earlier studies. 35, 36 However, the EUROSTAR international EVAR registry showed a perioperative mortality rate of 4.1% for AAAs $6.5 cm that was significantly higher than the 2.1% mortality for smaller AAAs <6.5 cm (P < .001). 11 Different from the EUROSTAR study, 11 our patients with smaller AAAs (group 1) had similar surgical risk to those with large AAAs (group 4). In a meta-analysis of 6090 patients undergoing EVAR, early mortality was 0% to 1.6% for small AAAs (<5.5 cm), lower than the 2% to 3.2% for large AAAs (>5.5 cm; odds ratio, 0.68; 95% CI, 0.51-0.90; test for heterogeneity, P ¼ .30). 37 Early device-related and endoleak-related complications as well as early reinterventions were more frequent in patients undergoing EVAR between1997 and 2005 compared with those who were operated on between 2006 and 2011. These were likely due in part to first-generation device-related issues and in part to the surgeons' learning curve in the earlier years as well. Our study confirmed that maximal aortic diameter $6.0 cm is an independent predictor of increased late all-cause mortality; it was 44% at 5 years, higher than for those with small AAAs (32%-35%; P < .001). When we compared outcome after EVAR vs OR using propensity score modeling, maximal aortic diameter increase per 1.0 cm was found to be a risk factor predicting all-cause late mortality. 3 Similar results were also reported in other studies, suggesting improved longterm survival after small AAA repairs. In a prospective multicenter clinical trial, Zarins et al 32 reported improved 5-year survival of 69% and 68%, respectively, following EVAR for small (<5.0 cm) and medium AAAs (5.0-5.9 cm) compared with the 51% for large AAAs ($6.0 cm). Sahal et al 38 observed 6-year survival rates of 66% for patients with small aneurysms (#5.5 cm) and 44% for larger aneurysms after 452 elective EVARs. Keith et al 33 reported 10-year survival rates of 72% for small (4.0-4.9 cm), 63% for medium (5.0-5.9 cm), and 50% for large AAAs ($6.0 cm; P < .001). These authors concluded that EVAR for small AAAs showed improved long-term outcome than for age-matched patients with larger AAAs. In the EUROSTAR study, both aneurysm-related and non-aneurysm-related mortality rates were significantly higher in patients with larger AAAs ($6.5 cm, 12% and 24%) than in patients with small (4.0-5.4 cm, 3% and 13%) and medium AAAs (5.5-6.4 cm, 5% and 18%) at 4 years.
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We observed no conversion surgery or late rupture in patients who had smaller AAAs (group 1); there were no differences between groups in terms of conversion and AAA rupture as well. Nevertheless, patients with AAA $6.0 cm had significantly increased late complications and reinterventions compared with group 1, particularly those related to endoleak. The EUROSTAR registry demonstrated that patients with an AAA >6.0 cm and a proximal aortic neck >26 mm have worse clinical outcome after EVAR. 29 Zarins et al reported increased
reinterventions and conversion to OR following EVAR for AAAs $5.5 cm vs AAAs <5.5 cm; however, there were no significant differences between small (<5.0 cm), medium (5.0-5.9 cm), and large AAAs ($6.0 cm). 14 Large AAAs tend to have short proximal aortic necks that often are angulated, contain thrombus, or are calcified, which may result in increased endoleakrelated complications and reinterventions. Differences in vascular biology, pathophysiology, and AAA anatomy between large and small AAAs may affect the outcome after AAA repair. Our retrospective study has several limitations as it may be confounded by the preoperative variables of age, gender, risk factors, and a variety of endografts used in EVAR. Four groups based on maximal aortic diameter were decided according to clinical judgment instead of statistical distribution or casematched cohorts. The correlation of AAAs $60 mm (group 4) with fewer female patients, advanced age, and a higher incidence of preoperative comorbidity is appreciable in this study. Maximal aortic diameter is the most commonly used quantitative criterion for screening, surveillance, and decision for intervention, whereas neck anatomy as well as the use of endografts within or outside of the instructions for use was not studied. Although we confined a maximum outer-to-outer AAA diameter from CT and CTA images in this study, three-dimensional measurement was not applicable in the early stage, and because the study period covered 15 years, measurement heterogeneity is possible. Aneurysm-related death was not defined because of the low autopsy rate in our population, making the diagnosis of aneurysm rupture as cause of death uncertain. The late outcome might be underestimated because of missing adverse events or loss of follow-up, and type II errors are likely.
CONCLUSIONS
Elective repair of asymptomatic patients with AAAs using EVAR is safe with an overall early mortality of 1%.
Patients with large AAAs ($6.0 cm) have higher late mortality after EVAR than those with smaller aneurysms (<5.0 cm). Compared with smaller AAAs (<5.0 cm), patients with large AAAs ($6.0 cm) have higher complication and reintervention rates, particularly those related to endoleak. High surgical risk may affect the outcome in patients with smaller AAAs. Our data support better overall outcome in patients who undergo EVAR for aneurysms <6.0 cm. We continue to recommend that AAAs be repaired when they reach 5.5 cm, as recommended by the guidelines of the SVS. On the basis of our data, EVAR should be considered even in high-risk patients with a maximal aortic diameter between 5.5 and 6.0 cm because surgical risk with aneurysm size above 6.0 cm will increase significantly.
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